ArticleOncogene2024
M
Erratum issuedAbstract read
In one paragraph
Article in Oncogene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 50 citations in OpenAlex.
- Natural products mediate ferroptosis and immune microenvironment-linked sensitization in osteosarcoma: from chemotherapy resistance to combined therapeutic transformation.Molecular diversity · 2026Review
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- RNA methylation in cell death: mechanisms and clinical applications.Molecular cancer · 2026Review
- TargetingZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Targeting Ferroptosis With Natural Products for the Treatment of Skeletal System Disease: An Updated Review.Journal of cellular and molecular medicine · 2026Review
- RNA modifications and cancer ferroptosis.Cancer cell international · 2026Review
- Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 mCell death & disease · 2026Article
- Emerging research themes in drug resistance in osteosarcoma: a 25-year bibliometric and visualized analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Identification of Key Bioactive Compounds of Medicine-Food Homologous Substances and Their Multi-Target Intervention Effects in Osteosarcoma Treatment.International journal of molecular sciences · 2026Article
- The Interplay Between Bone Biology and Iron Metabolism: Molecular Mechanisms and Clinical Implications.Biomedicines · 2026Review
- METTL3-mediated mMolecular cancer · 2026Article
- RNA Methylation in Cancer Metabolism: from Mechanisms to Therapeutic Opportunities.International journal of biological sciences · 2026Review
- Natural products reshape osteosarcoma cell fate: promoting cell death.Frontiers in pharmacology · 2026Review
- Tryptophan Suppresses FTH1-Driven Ferritinophagy, a Key Correlate of Prognosis in Hepatocellular Carcinoma.Cell proliferation · 2026Article
- MircoRNAs as regulators of regulated cell death in cancer progression: a focus on ferroptosis, anoikis and pyroptosis.Frontiers in pharmacology · 2026Review
- Identification of an m7G-Related lncRNA Signature for Prognostic Prediction and Immune Landscape Characterization in Early Gastric Cancer.OncoTargets and therapy · 2026Article
- MARCH8/NSUN6/ROS-mediated DNA damage positive feedback loop regulates cisplatin resistance in osteosarcoma.Cell death and differentiation · 2025Article
- Iron-Related Metabolic Targets in the Treatment of Osteosarcoma: Research Progress and Prospects.Biomedicines · 2025Review
- Exploring the Therapeutic Potential of MIR-140-3p in Osteoarthritis: Targeting CILP and Ferroptosis for Novel Treatment Strategies.Cell proliferation · 2025Article
- NSUN2 promotes leukemogenesis by ferritin heavy chain 1-mediated anti-ferroptosis and enhancing global protein synthesis in an mClinical epigenetics · 2025Article
Corrections and comments
- Erratum issuedCorrection: M2024
Authors and funding
21 authors at 1 institution in 1 country.
Mingyu He *National key laboratory of frigid cardiovascular disease, Harbin, China.
Yang Wang *Department of Pharmacy (The University Key Laboratory of Drug Research, Heilongjiang Province), The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Jiajie Xie *Department of Pharmacy (The University Key Laboratory of Drug Research, Heilongjiang Province), The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Jiaying PuDepartment of Pharmacy (The University Key Laboratory of Drug Research, Heilongjiang Province), The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zhihua ShenDepartment of Pharmacy (The University Key Laboratory of Drug Research, Heilongjiang Province), The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Ao WangNational key laboratory of frigid cardiovascular disease, Harbin, China.
Tao LiNational key laboratory of frigid cardiovascular disease, Harbin, China.
Tong WangNational key laboratory of frigid cardiovascular disease, Harbin, China.
Guanghui LiNational key laboratory of frigid cardiovascular disease, Harbin, China.
Ying LiuNational key laboratory of frigid cardiovascular disease, Harbin, China.
Zhongting MeiNational key laboratory of frigid cardiovascular disease, Harbin, China.
Zijing RenDepartment of Pharmacy (The University Key Laboratory of Drug Research, Heilongjiang Province), The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wenbo WangDepartment of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiaoyan LiuDepartment of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Jinhuan HongDepartment of Pharmacy (The University Key Laboratory of Drug Research, Heilongjiang Province), The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Qian LiuNational key laboratory of frigid cardiovascular disease, Harbin, China.
Hong LeiNational key laboratory of frigid cardiovascular disease, Harbin, China.
Xiaoqi HeNational key laboratory of frigid cardiovascular disease, Harbin, China.
Weijie DuNational key laboratory of frigid cardiovascular disease, Harbin, China.
Ye YuanNational key laboratory of frigid cardiovascular disease, Harbin, China. yuanye_hmu@126.com.ORCID 0000-0001-5722-1291
Lei YangDepartment of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, China. yangray83@vip.qq.com.
Harbin Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Doxorubicin and platinum are widely used in the frontline treatment of osteosarcoma, but resistance to chemotherapy limits its curative effect. Here, we have identified that METTL1 mediated N
Indexed as
Bone NeoplasmsFerroptosisMicroRNAsOsteosarcomaFerritinsHumansOxidoreductasesRNA, MessengerFerritinsFTH1 protein, humanMicroRNAsMIRN98 microRNA, humanOxidoreductasesRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.